Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
CS Diagnostics Corp. (CSDX)
Neuss, DE
Headquartered in Neuss, Germany, CS Diagnostics Corp. was established in 1996. The company is dedicated to the development, production, and worldwide distribution of a range of health and medical-grade products, catering to both domestic German and international markets. Among its key offerings are MEDUSA, an exclusive surface disinfectant, and CS-Protect Hydrogel, a specialized tissue-spacing gel for radiation therapy applications. The firm rebranded as CS Diagnostics Corp. in August 2023, having previously operated under the name FlashZero Corp.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -36.67% | -38.00% | -50.60% | -66.49% | -75.40% | -79.73% | -17.33% | -96.56% | -98.68% | -82.29% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+61.9% ★ Q4'25: -1,282.8% (vs Q3'24)
-
EPS growth Medical - Devices: +28.5%+250.0% ★
-
FCF margin FCF growth · Medical - Devices: +30.9%+34.9% Q4'25: +530,348.6% (vs Q3'24)
-
EBIT margin Medical - Devices: +6.2%+34.9% ★ Q4'25: -41.5% (vs Q3'24)
-
ROIC Medical - Devices: +3.3%+0.0% Q4'25: +0.0% (vs Q3'24)
-
Share dilution Medical - Devices: 0.0%+125.6% Q4'25: +92.6% (vs Q3'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×0.00× Q4'25: 0.00× (vs Q3'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-27 | B | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-26 | B | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-22 | B | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-21 | B | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-20 | B | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-19 | B | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-18 | B | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-15 | B | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-14 | B | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-13 | B | 3/5 | 3/5 | 3/5 | 3/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-12 | B | 3/5 | 3/5 | 3/5 | 3/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-11 | B- | 3/5 | 3/5 | 2/5 | 3/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-08 | B- | 3/5 | 3/5 | 2/5 | 3/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-07 | B- | 3/5 | 3/5 | 2/5 | 3/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-06 | B- | 3/5 | 3/5 | 2/5 | 3/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-05 | B- | 3/5 | 3/5 | 2/5 | 3/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-04 | B- | 3/5 | 3/5 | 2/5 | 3/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-01 | B- | 3/5 | 3/5 | 2/5 | 3/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-30 | B- | 3/5 | 3/5 | 2/5 | 3/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-29 | B | 3/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-28 | B | 3/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-27 | B | 3/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-24 | B | 3/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-23 | B | 3/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-22 | B | 3/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-21 | B | 3/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-20 | B | 3/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-17 | B | 3/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-16 | B | 3/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | CS Interpharm LLC | 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 49,362,500 | D | ↗ |
| 2025-12-31 | CS Interpharm General Trading Co. LLC | 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 42,560,096 | D | ↗ |
| 2025-12-31 | CS Diagnostics Pharma GmbH | 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 104,507,800 | D | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Janel Luzana | Corporate Secretary | — | female |
| Mohammad EsSayed | VP, CFO & Director | — | male |
| Sabrina Kummer Godehardt | Director of Business Development & Director | — | female |
| Thomas Fahrhoefer | President, Chairman & CEO | — | male |
| Thomas J. Migotsch | VP & COO | — | male |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CSDX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
